Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

[1]  F. Schmitt,et al.  EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy , 2008, Expert review of molecular diagnostics.

[2]  C. Boni,et al.  Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer , 2008, Breast Cancer Research and Treatment.

[3]  F. O'Malley,et al.  HER2/neu in systemic therapy for women with breast cancer: a systematic review , 2008, Breast Cancer Research and Treatment.

[4]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[5]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Sormani,et al.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.

[8]  J. Bartlett,et al.  Predictive markers in breast cancer – the future , 2007, Histopathology.

[9]  A. Buzdar.  Preoperative chemotherapy treatment of breast cancer—A review , 2007, Cancer.

[10]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. A. van der Hage,et al.  Preoperative chemotherapy for women with operable breast cancer. , 2007, The Cochrane database of systematic reviews.

[12]  S. Feldman,et al.  Primary systemic therapy of breast cancer. , 2006, The oncologist.

[13]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Baselga,et al.  Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Whang‐Peng,et al.  Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. , 2005, Cancer research.

[16]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[19]  M. Buyse,et al.  Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[21]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[22]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Nicholson,et al.  Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.

[24]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  G. Sherbet,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER , 1985, The Lancet.

[27]  D. Berry.  Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .

[28]  M. Morrow.  Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer , 2006 .